Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Fish and Richardson
QuintilesIMS
Healthtrust
Baxter
Queensland Health
Deloitte
Covington

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020559

« Back to Dashboard

NDA 020559 describes TRITEC, which is a drug marketed by Glaxosmithkline and is included in one NDA. Additional details are available on the TRITEC profile page.

The generic ingredient in TRITEC is ranitidine bismuth citrate. There are forty-three drug master file entries for this compound. Additional details are available on the ranitidine bismuth citrate profile page.
Summary for 020559
Tradename:TRITEC
Applicant:Glaxosmithkline
Ingredient:ranitidine bismuth citrate
Patents:0
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength400MG
Approval Date:Aug 8, 1996TE:RLD:No

Expired US Patents for NDA 020559

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Sign Up ➤ Sign Up
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Fuji
Covington
Mallinckrodt
Johnson and Johnson
QuintilesIMS
Federal Trade Commission
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.